HIFU Treatment for Prostate Cancer

High-Intensity Focused Ultrasound (HIFU) is an advanced, non-surgical treatment for localized prostate cancer that has gained significant clinical traction over the past decade. For men who want effective cancer control without the risks associated with surgery or the prolonged treatment schedule of radiation, HIFU treatment for prostate cancer offers a compelling alternative worth understanding in full.

At Atlanta Prostate Center, our board-certified urologists offer HIFU as part of a comprehensive suite of prostate cancer treatment options tailored to each patient's diagnosis, anatomy, and personal goals.

What Is HIFU Treatment?

HIFU stands for High-Intensity Focused Ultrasound. The procedure uses precisely directed beams of ultrasound energy to generate intense, localized heat within targeted areas of the prostate. That heat destroys cancerous tissue at the focal point of the beam while leaving surrounding structures, including nerves, the bladder, and the rectum, largely intact.

The treatment requires no incisions, no radioactive implants, and no extended hospital stay. It is performed on an outpatient basis, and most patients return home the same day.

HIFU can be delivered as a whole-gland treatment, targeting the entire prostate, or as a focal therapy, treating only the region where cancer has been identified on imaging. When used focally, the goal is to maximize cancer control while minimizing the impact on urinary continence and sexual function.

How Does the HIFU Procedure Work?

The HIFU procedure for prostate cancer is performed under anesthesia and typically completed in a single session lasting between one and four hours, depending on prostate size and the extent of treatment required.

Consultation and Evaluation

Before the procedure, your care team at Atlanta Prostate Center will review your PSA levels, Gleason score, biopsy results, and MRI imaging to confirm that HIFU is appropriate for your case. A personalized treatment plan is developed based on the location and extent of cancerous tissue within the gland.

Ultrasound Imaging and Targeting

On the day of the procedure, a small probe is placed transrectally to provide real-time, high-resolution imaging of the prostate. This allows the treating physician to map the gland with precision and identify exactly which areas require treatment.

Focused Ultrasound Delivery

Using the real-time imaging as a guide, the HIFU device delivers tightly focused ultrasound energy to the targeted tissue. The energy creates intense focal heat that ablates cancer cells while preserving surrounding nerves and adjacent structures. Delivery is automated and monitored continuously throughout the session.

Recovery

Most patients go home the same day. A temporary urinary catheter is typically placed for a short period to assist with urination during initial healing. Most men return to normal daily activity within a few days.

Follow-Up Care

PSA monitoring is an essential part of post-HIFU care. Levels are tracked at regular intervals to assess treatment response and identify any signs of recurrence early.

Who Is a Candidate for HIFU Prostate Cancer Treatment?

HIFU is best suited for men with localized prostate cancer, meaning cancer that has not spread beyond the prostate gland. It is mainly recommended for the following patients:

• Men with low-risk disease (Gleason 6 / Grade Group 1) who prefer treatment over active surveillance.
• Men with favorable intermediate-risk disease (Gleason 7, 3+4) where cancer is identifiable on MRI and confined to a specific region of the gland.
• Select men with unfavorable intermediate-risk disease (Gleason 7, 4+3) when the cancer is well-localized and anatomy is appropriate.
• Men with local recurrence following radiation therapy, for whom HIFU may be considered as a salvage treatment option.

HIFU is not recommended for men with large prostates, extensive multifocal disease, or high-risk cancer that has extended beyond the capsule of the gland. A thorough evaluation, including multiparametric MRI and a detailed review of biopsy results, is required to confirm candidacy on an individual basis.

HIFU Success Rate for Prostate Cancer

Clinical outcomes data for HIFU treatment are encouraging. Published studies in major urology journals have demonstrated strong cancer control rates in men with low- to intermediate-risk localized prostate cancer treated with whole-gland or focal HIFU. Multi-year biochemical recurrence-free survival rates are competitive with those reported for surgery and radiation in comparable patient populations.

For men treated with focal HIFU specifically, quality-of-life outcomes are particularly notable. Rates of urinary incontinence and erectile dysfunction following focal HIFU are substantially lower than those typically reported after radical prostatectomy, making it an important option for men who place high value on preserving function after treatment.

Outcomes depend on patient selection, disease characteristics, and the experience of the treating physician. HIFU is not appropriate for every diagnosis, which is why thorough individualized evaluation is essential before any treatment decision is made.

Potential Side Effects of HIFU for Prostate Cancer

As with any prostate cancer treatment, HIFU carries potential side effects, though the overall profile is favorable compared to more invasive approaches.

• Urinary symptoms: Some men experience temporary urinary retention, frequency, or irritation in the weeks following treatment. These typically resolve as healing progresses.
• Urinary incontinence: Rates of clinically significant incontinence following HIFU, particularly focal HIFU, are low. Whole-gland HIFU carries a modestly higher risk due to the extent of tissue treated.
• Erectile dysfunction: The risk of erectile dysfunction following HIFU is lower than with radical prostatectomy when nerve-sparing focal approaches are used. Results vary depending on baseline function, age, and treatment approach.
• Rectourethral fistula: This is a rare but serious complication. Risk is minimized through careful technique and appropriate patient selection.
• PSA bounce: Some men experience a temporary rise in PSA in the months following HIFU before levels decline. This is generally not a sign of recurrence and is monitored closely during follow-up visits.

Conclusion

HIFU treatment for prostate cancer represents a meaningful advance in the management of localized disease. Its outpatient format, favorable side-effect profile, and ability to preserve future treatment options make it a strong consideration for men with low- to intermediate-risk prostate cancer who want effective treatment without the recovery demands of surgery or the prolonged schedule of radiation.

The decision to pursue HIFU should always be made through a thorough, individualized discussion with an experienced specialist who understands both the biology of the cancer and the patient's priorities.